464 related articles for article (PubMed ID: 28903567)
1. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
2. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
4. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
Yu Q; Shi JM; Tao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
[TBL] [Abstract][Full Text] [Related]
6. Utility of flow cytometry studies in the management of patients with multiple myeloma.
Paiva B; Merino J; San Miguel JF
Curr Opin Oncol; 2016 Nov; 28(6):511-517. PubMed ID: 27606694
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.
Takamatsu H
Int J Hematol; 2020 Apr; 111(4):519-529. PubMed ID: 32034671
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
11. Multiple Myeloma Minimal Residual Disease.
Paiva B; García-Sanz R; San Miguel JF
Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
14. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
15. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
16. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
Paiva B; van Dongen JJ; Orfao A
Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
18. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
Alonso R; Cedena MT; Gómez-Grande A; Ríos R; Moraleda JM; Cabañas V; Moreno MJ; López-Jiménez J; Martín F; Sanz A; Valeri A; Jiménez A; Sánchez R; Lahuerta JJ; Martínez-López J
Am J Hematol; 2019 Aug; 94(8):853-861. PubMed ID: 31074033
[TBL] [Abstract][Full Text] [Related]
19. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
